Interleukin 23 inhibition associates with lower incidence of cardiovascular risk factor type diseases compared with biologic-naïve patients with psoriasis: A retrospective cohort study

J Am Acad Dermatol. 2024 Oct 16:S0190-9622(24)03007-X. doi: 10.1016/j.jaad.2024.09.063. Online ahead of print.

Authors

Ana Ormaza Vera¹, Chunghwan Ro¹, Waleed Adawi¹, Alexander Yap², Abby S Van Voorhees¹, Clinton W Enos³

Affiliations

¹ Department of Dermatology, Eastern Virginia Medical School, Macon & Joan Brock Virginia Health Sciences at Old Dominium University, Norfolk, Virginia.
² Department of Trial Design & Optimization, TriNetX, LLC, Cambridge, Massachusetts.
³ Department of Dermatology, Eastern Virginia Medical School, Macon & Joan Brock Virginia Health Sciences at Old Dominium University, Norfolk, Virginia. Electronic address: [email protected].

PMID: 39423931
DOI: 10.1016/j.jaad.2024.09.063

No abstract available

Keywords: MACEs; biologics; cardiovascular risk; diabetes; dyslipidemia; hypertension; incidence; inflammatory; psoriasis; psoriasis therapy.